**Name of Journal: *World Journal of Radiology***

**ESPS Manuscript NO: 21477**

**Manuscript Type: Review**

**Computed tomography dose optimisation in cystic fibrosis: A review**

Ferris *et al*. CT dose in cystic fibrosis

**Helena Ferris, Maria Twomey, Fiachra Moloney, Siobhan B O’ Neill, Kevin Murphy, Owen J O’ Connor, Michael Maher**

**Helena Ferris, Maria Twomey, Fiachra Moloney, Siobhan B O’ Neill, Kevin Murphy, Owen J O’ Connor, Michael Maher,** Department of Radiology, Cork University Hospital, Wilton, 001 Cork, Ireland

**Author contributions:** Ferris H was the primary author and drafted the manuscript; Twomey M, Moloney F and O’ Neill SB conducted the literature review and drafted sections of the manuscript; Murphy K and O’ Connor OJ edited the manuscript; Maher M drafted the study concept plus was involved in and oversaw all aspects of the review.

**Conflict-of-interest** **statement:** No potential conflict of interest. No financial support.

No supporting foundations.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Fiachra Moloney, MD,** Department of Radiology, Cork University Hospital, 1 Bishopstown Road, Wilton, 001 Cork, Ireland. fiachramoloney@hotmail.com

**Telephone:** +353-21-4922000

**Fax:** +353-21-4922002

**Received:** July 15, 2015

**Peer-review started:** July 17, 2015

**First decision:** September 28, 2015

**Revised:** January 5, 2016

**Accepted:** January 16, 2016

**Article in press:**

**Published online:**

**Abstract**

Cystic fibrosis (CF) is the most common autosomal recessive disease of the Caucasian population worldwide, with respiratory disease remaining the most relevant source of morbidity and mortality. Computed tomography (CT) is frequently used for monitoring disease complications and progression. Over the last fifteen years there has been a six-fold increase in the use of CT, which has lead to a growing concern in relation to cumulative radiation exposure. The challenge to the medical profession is to identify dose reduction strategies that meet acceptable image quality, but fulfil the requirements of a diagnostic quality CT. Dose-optimisation, particularly in CT, is essential as it reduces the chances of patients receiving cumulative radiation doses in excess of 100 mSv, a dose deemed significant by the United Nations Scientific Committee on the Effects of Atomic Radiation. This review article explores the current trends in imaging in CF with particular emphasis on new developments in dose optimisation.

**Key words:** Cystic fibrosis; Computed tomography; Dose; Dose optimization; Ionising radiation; Kalydeco

© **The Author(s) 2016**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** There is a growing reliance on the use of computed tomography (CT) in the management of cystic fibrosis (CF), as demonstrated by a six-fold increase in the use of CT in CF over the last fifteen years. There are concerns over repeated patient exposure to ionising radiation and the potential carcinogenic consequences. With the ever-increasing life expectancy of patients with CF and a predilection for certain cancers, it is important to be aware of cumulative radiation exposure from radiological imaging. Dose-optimisation, particularly in CT, is therefore essential.

Ferris H, Twomey M, Moloney F, O’ Neill SB, Murphy K, O’ Connor OJ, Maher M. Computed tomography dose optimisation in cystic fibrosis: A review. *World J Radiol* 2016; In Press

**INTRODUCTION**

Cystic fibrosis (CF) is the most common autosomal recessive disease of the Caucasian population worldwide, with an incidence of approximately 1 in 3000 live births[1]. This multisystem disorder is characterised by irreversible lung destruction, gastrointestinal malfunction and exocrine insufficiency. Respiratory disease remains the most relevant source of morbidity and mortality, and accounts for over 80% of deaths[2]. Consequently, thoracic imaging plays a pivotal role in monitoring disease complications and progression.

Computed Tomography (CT) in particular has been increasingly used to evaluate CF patients. Over the last fifteen years there has been almost a six-fold increase in the use of CT scanning in CF[3]. This trend can be attributed to the widespread availability of CT, rapid acquisition time and the high sensitivity and specificity for lung and gastrointestinal disease. However, there are growing concerns over repeated patient exposure to ionising radiation and the potential carcinogenic consequences. With the ever-increasing life expectancy of CF patients and a predilection for certain cancers, cumulative radiation exposure from radiological imaging is receiving increasing scrutiny[4,5]. This review explores the current imaging trends in CF with particular emphasis on new developments in dose optimisation.

**CT USE AND CUMULATIVE EFFECTIVE DOSE**

During their lifetime, it is estimated that CF patients will have on average 3.2 thoracic CT scans (range 0-13)[6], which results in cumulative effective doses (CEDs) in excess of the general population. There are many reasons for this including the length of time patients suffer from the disease and the accuracy of CT in the setting of CF. Thoracic imaging often begins during infancy; as the earliest radiological manifestation of CF, mucous plugging, can be detected using radiological imaging. As the illness progresses, scanning is often required to assess deteriorating lung structure and function caused by chronic infection and inflammation secondary to bronchiectasis.

Quantification of CF bronchiectasis using CT bronchiectasis scores has been found to be more sensitive for assessing the degree of lung destruction, compared with pulmonary function test (PFT) parameters obtained through pulmonary function testing[7,8]. In recent years studies have reported discordance between changes in CT score and PFTs within patient cohorts. In essence, both investigations look at different aspects of the disease; CT assesses structural change while PFT’s evaluate lung function. In one paper, CT bronchiectasis scores deteriorated 70% faster than PFT parameters, including forced expiratory volume in one second (FEV1) in a third of adults and children studied, suggesting that CT is more sensitive than PFT assessment at detecting deterioration[7].

The poor sensitivity of PFT’sfor changes in lung function and the ability of CT to rapidly track declining lung function, has implications for use of CT imaging for disease management, and CT may provide useful information to inform management decisions such as when to escalate drug therapy or when lung transplantation is necessary[9-11]. Multiple studies have also demonstrated that CT is more sensitive than chest radiography in detecting pulmonary deterioration[12-15].

This increased utilisation of CT further increases the lifetime CED in these patients. A recent multi centre study of CT in CF patients between 1990-2005 showed that CT scores were a significant independent predictive factor for survival post-transplant[16]. Information gained from CT is therefore very useful, considering that up to one-third of CF patients will meet criteria for lung transplantation[13].

Assessment of disease severity by CT provides a more objective, reproducible and accurate representation of patient’s disease burden. Clinical trials increasingly use CT to monitor response to antibiotics and gene therapy in the treatment of CF[17,18]. Although quantification of changes in disease severity by CT closely correlates with the frequency of infective exacerbations and disease progression[19,20], one must remain cognisant of the radiation dose incurred from this method of assessment[21]. Recent studies have shown that the dose from dose optimised CT scans is equivalent to one-third of one year’s background radiation[22]. Perhaps the risk of sequential scanning is justified due to the high morbidity and reduced life expectancy related to CF[23,24].

The radiation dose incurred by patients with CF through medical imaging has recently been studied in Ireland, which has the highest worldwide incidence of cystic fibrosis[1]. During the 15-year study period, there was a 5.9 fold increase in all CT imaging[3,25] with an associated increase in CED among hospitalised CF patients[26,27]. In fact, the annual CED from medical imaging has been steadily increasing over the last 30 years. For instance the mean annual effective dose for CF patients has increased incrementally from 0.39 mSv to 0.47 mSv and then to 1.67 mSv per person per year over the last three decades. A similar study demonstrated comparable findings in a French context, where it was found that the mean CED in a cohort of CF patients was 19.5 mSv (range 2.24-78.5 mSv)[6]. Donadieu *et al*[6] also found that the patient age at the time of their first CT scan has decreased from 20 years in those born before 1980 to 1.9 years in those born after 1997 again reflecting the increased utilisation of CT in this patient group.

O’Connell *et al*[3] demonstrated that thoracic imaging accounted for 46.9% of the total CED, closely followed by abdominopelvic imaging, which was responsible for 42.9% of CED. This may be representative of a trend to image the thorax, abdomen and pelvis together routinely as opposed the chest only. It may also reflect increasing use of CT scanning for investigating abdominal complications in CF patients, who are living longer as a result of improved respiratory treatments, which leads to improved life expectancy among CF patients; now extending to between 35 and 40 years[28]. These changing trends in radiation exposure among CF patients need to be closely monitored[29].

The expanding use of CT for guidance of medical management, particularly in patients with chronic relapsing illnesses such as inflammatory bowel disease and CF, has highlighted the need for strategies to optimise dose from imaging, especially CT. CT is responsible for only 15% of imaging procedures in inflammatory bowel disease but contributes over 75% of the CED[30]. The use of diagnostic imaging studies which result in exposure to ionising radiation in CF patients is of particular concern due to the greater vulnerability of younger patients to radiation induced injury due to their inherent radio-sensitivity[31], early onset of illness and greater risk of high cumulative exposures throughout their lifelong illness.

**ROLE OF CHEST MAGNETIC RESONANCE IMAGING AND OTHER ALTERNATIVES IN PATIENTS WITH CF**

Although CT is considered the gold standard for assessing CF patients, there may be a role for use of complementary imaging modalities such as pulmonary magnetic resonance imaging (MRI)[32]. MRI is less sensitive for detection of small airways disease but is superior for assessing functional change such as changes in pulmonary perfusion[33,34].Many authors advocate a role for the use of MRI in the follow-up of morphological changes in CF, however[35-37],the combination of MRI with inhaled hyperpolarised helium is also gaining in popularity[38-42]. The utilisation of inhaled agents such as hyperpolarised helium or xenon gives functional information regarding gas exchange. Obvious disadvantages are cost and time for acquisition in addition to limited usefulness in the ventilated or critical patient.

Fluorodeoxyglucose positron emission tomography - computed tomography has been utilised with some success in delineating areas of active infection from fibrosis[43,44] but access, cost and radiation dose are clear constraints hence mainstream use cannot be advocated.

**RADIATION RISK FROM MEDICAL IMAGING**

There is no proven association between radiation exposure in the diagnostic range and the development of malignancy. Predictions of the effects of medical-induced exposure to low-dose ionising radiation are largely based on data from the survivors of atomic bomb blasts or nuclear accidents. For the purpose of risk estimation, cancer incidence in this cohort was extrapolated from doses greater than 100 mSv to doses of a few mSv[45], using a linear no- threshold model. However, this model is being challenged as it conflicts with the current understanding of the biological mechanism of radiation-induced injury. Recently, The United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), reported uncertainty in relation to the health effects of low-dose radiation. Based on findings from the nuclear accident in Fukushima 2012, doses of 100 mSv per year were deemed to have no observable acute or chronic effects on cancer incidence rates or public health[46].

The risk of radiation-induced cancer at doses less than 100 mSv is believed by some to be too small to be distinguishable from other risk factors for development of cancer[47,48]. However, a recently published retrospective cohort study, studied the risk of leukaemia and brain tumours associated with CT scans performed during childhood. Based on the findings of the study, the authors estimated that in the ten years after the first CT scan was performed in patients younger than ten years, that one excess case of leukaemia and one excess case of a brain tumour per 10000 head CT scans occurred[49]. This association is particularly pertinent in CF where the average age at first CT scan is 1.9 years[27]. Some studies have suggested that there is an exponential increase of radiation induced cancer with decreasing age at initial exposure, namely, there is an estimated 14% lifetime cancer mortality risk per Gy in patients first exposed under the age of 14 years compared to a 5% risk in those first exposed in their 50’s[50,51].

It is vital that the radiologist, referring physician and technologist ensure that the immediate benefits of CT are likely to outweigh the long-term risks before performing a CT scan. Refinements in CT scanner hardware and software and development of low-dose scanning protocol can lead to substantial reductions in radiation exposure from CT scanning while preserving image quality. These efforts are ensuring that CT scans can now be performed at much lower doses and that image quality is preserved in-spite of radiation dose reductions.

**OPTIMISATION OF CT PARAMETERS**

There is major industry and clinical impetus to develop and implement strategies that will reduce the effective doses incurred by patients undergoing CT without sacrificing diagnostic capabilities. The balance between image quality and radiation dose is particularly important where dose reduction is contemplated. Image noise is inversely related to X-ray beam energy and is an important determinant of image quality[52]. There are several scanning parameters that affect the radiation dose associated with CT, namely: Tube current, tube voltage, scanning length, collimation, table speed, table pitch, gantry rotation time and shielding[53].

Modifications of tube current and tube voltage have direct effects on radiation dose but also on image “mottle” or noise. There is thus a “balancing act” between radiation exposure imparted and image quality, which can impact ability to detect and characterise pathological processes on the CT images. In most CT scanners, tube current is adjustable in increments from 20 mAs to approximately 400 mAs. In practice, reduction in tube current is the most practical means of reducing CT radiation dose, with a 50% reduction in tube current leading to a 50% reduction in dose[54]. This strategy increases image noise and so must be validated prior to clinical use. Lucaya *et al*[55] studied the effects of image acquisition using 50 and 180 mAs in CT scanning of the chest in children and young adults. Imaging with 50 mAs lead to a 72% reduction in dosebut no difference in image quality compared with imaging at 180 mAs[55]. Another group have shown that high-resolution CT images of lung parenchyma acquired at 40 mAs yield anatomic information equivalent to that obtained at 400 mAs, without significantly affect subjective image quality[56].

Tube voltage affects both image noise and tissue contrast[57]. For instance, in abdominal CT, most scans can be optimally performed at 120 kVp instead of 140 kVp, resulting in a 20%-40% reduction in radiation dose[58]. The cross sectional dimensions of patients must be taken into consideration as the attenuation of the incident X ray beam depends on the anatomical region being evaluated[59]. Essentially, larger patients require a higher tube voltage. This also applies to tube current where Donnelly *et al*[60] have shown that acceptable image quality can be produced at 50% reduced tube current in patients weighing less than 81.6 kg. However, above this weight, images are too noisy. Therefore, scanning parameters should be tailored towards the patient characteristics, especially body mass index, in order to reduce dose.

Multiple other user-defined controllable parameters of CT imaging have an impact on radiation dose. In helical scanners, beam collimation, table speed and pitch are interlinked parameters that affect the diagnostic quality of an image. Pitch is defined as the ratio of table feed per gantry rotation to the nominal width of the X-ray beam[54]. A faster table speed results in a higher pitch and scanning at a higher pitch is more dose effective[61]. Technological advances such as sixty-four and one hundred and twenty eight detector row scanners have resulted in higher scanning speeds. For instance, a four row scanner with a 0.8 s gantry rotation time requires sixteen seconds to scan the entire abdomen. An eight row scanner, on the other hand, covers the same length in eight seconds[62]. Sixty-four slice scanners can acquire a whole body scan in less than 10 s and static organ imaging in 1 s[63]. This emphasises the importance of being aware that if tube rotation time is decreased (faster gantry rotation) radiation exposure decreases.

Furthermore, there is a general tendency to increase the area of coverage to include regions beyond the actual region of interest[64]. This increases the scanning length and thus unnecessarily increases doses that patients receive. It is essential for referring physicians to be mindful of this when requesting CT scans and for operators to restrict CT examinations to anatomical area that requires investigation. In addition, radiosensitive structures frequently lie close to the beam pathway. Adequate shielding is crucial, especially in the paediatric and young adult population whose organs are inherently more radiosensitive[65]. Beaconsfield *et al*[66] studied the effect of shielding regions of the body that are not included directly in the path of the X-ray beam during CT. They reported that with lead protection, thyroid and breast radiation doses were reduced by an average of 45% and 76% respectively[66]. This is particularly relevant in CF where an intrinsic risk of malignancy may be coupled with repetitive exposure to ionising radiation, rendering them particularly vulnerable.

***Automatic exposure control***

There have been many recent technological advances aimed at dose optimisation, including automatic exposure control (AEC). Automatic tube current modulation (ATCM) is a type of AEC, that works on the premise that pixel noise on a CT scan is attributable to quantum noise in the projections[67]. By adjusting the tube current to follow the changing patient anatomy, quantum noise projections can be adjusted to maintain a desired level of noise and improve dose efficiency[54]. Modern scanners use either one of two methods of ATCM - namely Z-axis modulation or angular modulation. In Z-axis modulation the tube current is adjusted to a user selected noise level[68]. Angular modulation on the other hand, attempts to render all images with similar noise regardless of patient size and anatomy[69]. The main advantage of ATCM is a reduction in dose with minimal compromise to image quality. This was highlighted by Greess *et al*[70] who reported a mean dose reduction of 22.3 % for CT scanning of the neck, thorax and abdomen in children without loss of image quality.

Special attention is required in patients with metallic prostheses, *i.e.,* heart valves or anatomical shielding. As ATCM adapts the tube current based on density and attenuation in the region, there is potential for an increase in tube current when metal is in the field of interest[71]. In the presence of metallic prostheses, the use of *z-*modulation has been reported to result in a 34.1% increase in the mean tube current time product for abdominopelvic CT. It is important to acknowledge that this is still substantially less dose than when using fixed tube scanning - *i.e.,* there is a reduction in dose of almost 30% with ATCM as opposed to fixed tube scanning[72]. With that said, it is imperative that we are aware of the presence of metallic prostheses in the scanning field so that an increase in radiation dose with *z-*modulation technique can be avoided by selection of lower maximum milliamperage thresholds or by using higher noise index or mixed modulation methods[73].

Radiation exposure can be further optimised by using X–ray filters, noise reduction filters and newer methods of image reconstruction such as iterative reconstruction, which we will discuss in greater detail at a later stage in this article.

**ITERATIVE RECONSTRUCTION**

As we have already explored in this review, increased image noise and reduced image quality are potential unfortunate consequences of reducing CT radiation dose. Standard CT scanners use filtered back projection (FBP) for image reconstruction. However, newer algorithms using iterative reconstruction (IR) have been introduced to reconstruct image data using a system of models which improve image noise. IR uses raw data as a building block whereby it transforms the measured value of each pixel to a new ideal estimate for that pixel[74]. This method uses matrix algebra and is repeated until the final estimated and ideal pixel values ultimately converge[75]. The use of IR extracts noise from CT images acquired at reduced exposure preserving image quality and interpretability[76]. The main advantage is that IR allows significant reductions in radiation dose while maintaining satisfactory image quality when compared to traditional FBP[74,77].

Hybrid iterative reconstruction, which combines both IR and FBP in a predefined ratio for image reconstruction, has been well validated in coronary CT angiography and for low dose CT scanning of the abdomen and pelvis in chronic conditions such as inflammatory bowel disease[78]. Multiple commercially available hybrid iterative reconstruction packages are available - these include adaptive statistical iterative reconstruction (ASiR) (GE Medical Systems, Milwaukee, WI, United States), adaptive iterative dose reduction (AIDR) (Toshiba Medical Systems, Tochigi, Japan), image reconstruction in image space (Siemens Healthcare, Erlangen, Germany), sinogram-affirmed iterative reconstruction (Siemens Healthcare) and iDose (Philips Healthcare, Best, Netherlands). Craig *et al*[30] compared hybrid IR of low-dose CT abdomen-pelvis datasets with conventional-dose CT in Crohn’s disease and reported a 74% radiation dose reduction with IR. IR operates on list-mode data as opposed to histogrammed projection data and can generate an image following just one pass through the scan[79]. This results in a shorter scanning timeand a reduction in radiation-exposure associated with CT thorax to a level approaching that of a plain radiograph[80]. The use of low dose CT with IR is ideal for imaging CF patients and in particular, the paediatric CF population.

In relation to thoracic imaging, ASIR has been shown to significantly reduce subjective and quantitative image noise on both standard and reduced dose chest CT[81]. Dose reductions of 46%-80% for thoracic CT can be achieved without compromising image quality[82,83]. In practice, this translates to substantial dose reductions in paediatric CT imaging without substantial compromise in image quality, a strategy that can be applied to imaging in CF[84].

Next generation imaging reconstruction will be performed using “pure” iterative reconstruction such as model-based iterative reconstruction (MBIR, Veo, GE Healthcare), iterative model reconstruction (Philips Healthcare), advanced modeled iterative reconstruction (ADMIRE, Siemens Healthcare) and AIDR 3D (Toshiba Medical Systems). Pure iterative reconstruction generates high quality images[85] with an even greater reduction in dose than hybrid IR, for example in excess of 80% dose reduction[86]. MBIR facilitates ultra-low dose chest imaging and a number of studies suggest that image quality can be maintained at doses approaching those of a chest radiograph[87,88]. However, the prolonged processing time currently limits its use in routine clinical practice especially for emergency cases. In the case of outpatient imaging for chronic disease assessment, such as in the setting of CF, an hour of reconstruction time is acceptable for the benefits gained.

**DOSE OPTIMISATION PROTOCOLS**

The purpose of CT dose optimisation is to obtain a diagnostic image with the least amount of radiation. Dose optimisation strategies are a priority among imaging specialists. Thoracic CT is particularly suited to dose optimisation protocols due to the high inherent contrast and low radiation absorption of the lung[89]. Recent studies have explored the utilisation of low dose protocols for thin-section CT in the assessment of CF. O’ Connor *et al*[90] compared two non-contiguous thin-section protocols: protocol A (1 mm section with an effective dose 0.19 mSv) and protocol B (0.5 mm section with an effective dose 0.14 mSv) reconstructed using filtered back projection and using a 4-slice CT scanner. Diagnostic acceptability was graded as almost excellent for both protocols, however, the 0.5 mm section was found to be inferior for mediastinal assessment[90]. This study emphasised the fact that low-dose thin section CT is a viable option for accurately evaluating pathological changes in the lungs of CF patients even at doses approaching those of a chest radiograph.

As described above, recent advances in the area of radiation dose optimization and CT have focussed on refinement of iterative reconstruction techniques to allow diagnostic quality images to be acquired at significantly reduced radiation doses. IR when applied to thoracic imaging in CF patients should potentially allow contiguous chest imaging at chest X-ray doses which would improve scanning time and reduce the requirement for repeated patient breath-holds, which has potential for error. Contiguous CT scanning through the chest will facilitate 3D reconstruction that allows more comprehensive characterisation of distribution of lung changes, facilitates comparison with previous chest radiography and may offer potential for virtual bronchoscopy. Most recently, Singh *et al*[91] showed that ASiR reconstructed chest CT images can be obtained at 40 mAs/3.5 mGy and still be diagnostically satisfactory.

Thin-section protocols have great potential for use in the paediatric CF population where an effective dose reduction of 26% can be achieved without compromising image quality[92]. There may also be a role for low-dose protocols in non-CF bronchiectasis, which accounts for 10% of referrals to tertiary respiratory centres[15]. In 50% of these new referrals, patients are misdiagnosed with asthma until the true diagnosis is confirmed at CT[93,94]. Once a diagnosis of CF is established, some experts suggest that low-dose CT should be performed bi-annually for assessment of lung parenchyma and bronchoalveolar structures in place of chest radiography[95].

Furthermore, substantial reductions in radiation dose can be achieved using only end expiratory CT in CF as opposed to combined end inspiratory and end expiratory CT. Loeve *et al*[96] reported a 75% reduction in effective dose when using low-dose (0.4 mSv, 110 kV) end expiratory CT alone while maintaining high inter-observer correlation of CF CT scores. Expiratory chest imaging can provide useful detail when air trapping is suspected, as this may not be appreciated on inspiratory CT[97]. Expiratory CT identifies small airways disease (SAD) and ideally should be controlled by spirometry[98,99]. SAD is recognised by the presence of hypo-dense areas within areas of mosaic attenuation and it is estimated that one third of hypo-dense regions persist over a two year period, which suggests irreversibility[12]. This may be used as a separate marker of pulmonary disease in conjunction with CT bronchiectasis scores.

As a large proportion of CF patients are in the paediatric age group, compliance with scanning methods can be difficult to achieve. Methods of optimising patient cooperation help maximise the information obtained from CT by reducing breathing artefact and the need for repeat imaging. Training in breath holding techniques, lateral decubitus positioning or spirometry may prove beneficial in this regard. In children less than 5 years old, sedation may be required to avoid multiple scans due to movement or inability to follow instructions[100].

Surprisingly, there are no clear data on how CT-guided decision making affects outcome in CF patients[101]. Owing to the accurate depiction of disease progression, however, low-dose CT scans are regularly used to guide management in clinical practice. In many dedicated CF centres, dose-optimised CT is performed bi-annually. PFT’s are often used in conjunction with CT as part of a multi-modal assessment, especially between CT scans. Disease models that encompass age, gender, CT and PFT’s can be used as a guide to predict frequency of infective exacerbations or the rate of decline in lung function. Although these models are not yet fully validated, they represent a move towards personalised treatment. For instance, some “low-risk” patients may only need CT scans every three years as opposed to “high-risk” patients who may need annual scanning. The 2009 CF guidelines do not recommend any specific scanning frequency or interval but recommend CT in symptomatic patients who fail to respond to basic intervention[102]. Ideally, CF management should be personalised and based on risk stratification.

**SCREENING IN RESPIRATORY DISEASE**

Dose optimisation scanning techniques have facilitated the use of CT as first line imaging and are gaining popularity for screening of benign and malignant respiratory conditions. Most notably, The American Association for Thoracic Surgery recently published guidelines on screening for lung cancer, which recommend annual dose-optimised CT screening for patients aged 55-79 year with a greater than 30 year pack history[103-105]. These guidelines were derived from the National Lung Screening Trial, which established the ability of dose-optimised CT to decrease lung cancer specific mortality by 20% in a screened population[104]. As the role of CT in the medical arena expands, so does the need for dose-optimisation strategies so that low dose scanning becomes commonplace.

**PHYSICIAN AWARENESS**

Increasing concern has recently been expressed in the literature that the knowledge of referring doctors regarding the radiation doses incurred during diagnostic radiological procedures is inadequate[106]. Lee *et al*[107] found that 75% of physicians underestimate the dose from a CT scan. This is interesting considering the integral and expanding role that CT plays across all medical specialities and the utilisation of CT in the hospital setting where CT accounts for 15%of the workload of an average radiology department[108]. This shortcoming is also evident in medical students. O’Sullivan *et al*[109] assessed medical students’ awareness of radiation exposure associated with diagnostic imaging and found that only two-thirds of students knew that CT used ionising radiation. This lack of awareness becomes particularly pertinent when one considers the number of patients who receive inappropriate or repeat examinations[64,110]. Fortunately, education in clinical radiology positively impacts on knowledge of radiation exposure associated with diagnostic imaging, which supports the Eurotom 97 directive for the integration of radiation protection instruction into medical school curriculum[111]. As seen in the “Image wisely” and “Image Gently” campaigns, a three-tiered approach to radiation protection is strongly recommended: the as low as reasonably achievable principal, justification of the imaging procedure and dose limitation[112,113]. In short, the best way to reduce the radiation dose to patients is to avoid unnecessary CT exams and to look for alternative diagnostic imaging modalities which either avoid radiation exposure or result in less exposure than modalities[114]. Education of medical undergraduates and postgraduates is fundamentally important to ensure that radiation protection issues are considered when physicians choose the diagnostic imaging studies for their patients.

A new initiative on this front is the introduction of patient radiation dose tracking[115-117]. This entails detailed automated recording of all medical radiation exposures received by patients. This information can be included in individual radiology reports and medical files plus can be used to calculate lifetime cumulative exposures. This knowledge would then be available at the image requesting stage to keep clinicians aware of the patients past radiation exposures. Another powerful aspect of dose tracking is for quality assurance purposes within the imaging department, such that per study doses can be reduced to defined international standards.

**THE CHANGING FACE OF CF**

There is a constant stream of novel approaches to the management of CF. Most notably, the development of the first disease modifying drug in CF, Kayldeco, has opened up a new realm of possibilities using genomically-guided medicine[118]. In 2012, Kayldeco was approved by the food and drug administration for use in CF patients with the G551D mutation. Although this particular mutation is only found in approximately 5% of CF patients, it represents a significant breakthrough as it targets the underlying genetic defect within the *CFTR* gene[119]. Drug trials have demonstrated that Kalydeco can markedly improve lung function; lower sweat chloride levels and help patients gain weight[120]. Research is ongoing into the possible benefits of Kayldeco in the most common CF mutation: delta F508, which accounts for 70% of mutations. Results from a phase 2 trial of Kalydeco in combination with VX-809 show a marginal improvement in lung function in people who are homozygous for delta F508[68,121]. These developments have the potential to significantly improve quality of life for CF patients, however, the beneficial effects on the architecture of the lung, as seen on radiological imaging, have not yet been documented. This is an area of potential future research and another reason for optimisation of CT scanning protocols.

**RECOMMENDATIONS**

There is a growing reliance on the use of CT in the management of CF, as demonstrated by the six-fold increase in the use of CT in CF over the last fifteen years.

Dose-optimised CT reduces the chances of patients receiving cumulative radiation doses in excess of 100 mSv, a dose deemed significant by UNSCEAR.

Longitudinal studies are needed to define appropriate scanning intervals and to assess the impact of CT scanning on disease outcome in CF patients.

Physicians are developing tailored approaches to disease surveillance, where scanning intervals are based on risk stratification in order to maximise benefit.

**CONCLUSION**

As modern treatments continue to extend the life expectancy of CF patients, cumulative radiation exposure from medical imaging is of increasing significance. Medical professionals are challenged with identifying CT dose-reduction strategies that strike an acceptable balance between image quality and diagnostic acceptability. Dose optimisation strategies have to be continually developed and refined in all patients, but particularly those with chronic diseases such as CF, who will require radiological imaging throughout their lifetime.

**REFERENCES**

1 **Debray D**, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. *J Cyst Fibros* 2011; **10** Suppl 2: S29-S36 [PMID: 21658639 DOI: 10.1016/S1569-1993(11)60006-4]

2 **Wood BP**. Cystic fibrosis: 1997. *Radiology* 1997; **204**: 1-10 [PMID: 9205213 DOI: 10.1148/radiology.204.1.9205213]

3 **O'Connell OJ**, McWilliams S, McGarrigle A, O'Connor OJ, Shanahan F, Mullane D, Eustace J, Maher MM, Plant BJ. Radiologic imaging in cystic fibrosis: cumulative effective dose and changing trends over 2 decades. *Chest* 2012; **141**: 1575-1583 [PMID: 22207674 DOI: 10.1378/chest.11-1972]

4 **Bush A**. Treatment of cystic fibrosis: time for a new paradigm? *Chest* 2009; **136**: 1197-1199 [PMID: 19892669 DOI: 10.1378/chest.09-1523]

5 **Dodge JA**, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. *Eur Respir J* 2007; **29**: 522-526 [PMID: 17182652 DOI: 10.1183/09031936.00099506]

6 **Donadieu J**, Roudier C, Saguintaah M, Maccia C, Chiron R. Estimation of the radiation dose from thoracic CT scans in a cystic fibrosis population. *Chest* 2007; **132**: 1233-1238 [PMID: 17890474 DOI: 10.1378/chest.07-0221]

7 **de Jong PA**, Lindblad A, Rubin L, Hop WC, de Jongste JC, Brink M, Tiddens HA. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. *Thorax* 2006; **61**: 80-85 [PMID: 16244089 DOI: 10.1136/thx.2005.045146]

8 **Judge EP**, Dodd JD, Masterson JB, Gallagher CG. Pulmonary abnormalities on high-resolution CT demonstrate more rapid decline than FEV1 in adults with cystic fibrosis. *Chest* 2006; **130**: 1424-1432 [PMID: 17099020 DOI: 10.1378/chest.130.5.1424]

9 **Helbich TH**, Heinz-Peer G, Fleischmann D, Wojnarowski C, Wunderbaldinger P, Huber S, Eichler I, Herold CJ. Evolution of CT findings in patients with cystic fibrosis. *AJR Am J Roentgenol* 1999; **173**: 81-88 [PMID: 10397104 DOI: 10.2214/ajr.173.1.10397104]

10 **Cademartiri F**, Luccichenti G, Palumbo AA, Maffei E, Pisi G, Zompatori M, Krestin GP. Predictive value of chest CT in patients with cystic fibrosis: a single-center 10-year experience. *AJR Am J Roentgenol* 2008; **190**: 1475-1480 [PMID: 18492894 DOI: 10.2214/AJR.07.3000]

11 **Robinson TE**, Leung AN, Northway WH, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Hubli S, Moss RB. Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. *J Pediatr* 2001; **138**: 553-559 [PMID: 11295720 DOI: 10.1067/mpd.2001.111820]

12 **Cortese G**, Malfitana V, Placido R, Ferrari A, Grosso B, De Rose V, Nespoli P, Fava C. Role of chest radiography in the diagnosis of allergic bronchopulmonary aspergillosis in adult patients with cystic fibrosis. *Radiol Med* 2007; **112**: 626-636 [PMID: 17657421 DOI: 10.1007/s11547-007-0169-x]

13 **Sanders DB**, Li Z, Brody AS, Farrell PM. Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis. *Am J Respir Crit Care Med* 2011; **184**: 816-821 [PMID: 21737586 DOI: 10.1164/rccm.201105-80160C]

14 **Logan PM**, O'Laoide RM, Mulherin D, O'Mahony S, FitzGerald MX, Masterson JB. High resolution computed tomography in cystic fibrosis: correlation with pulmonary function and assessment of prognostic value. *Ir J Med Sci* 1996; **165**: 27-31 [PMID: 8867494 DOI: 10.1007/BF02942797]

15 **Eastham KM**, Fall AJ, Mitchell L, Spencer DA. The need to redefine non-cystic fibrosis bronchiectasis in childhood. *Thorax* 2004; **59**: 324-327 [PMID: 15047953 DOI: 10.1136/thx.2003.011577]

16 **Loeve M**, Hop WC, de Bruijne M, van Hal PT, Robinson P, Aitken ML, Dodd JD, Tiddens HA. Chest computed tomography scores are predictive of survival in patients with cystic fibrosis awaiting lung transplantation. *Am J Respir Crit Care Med* 2012; **185**: 1096-1103 [PMID: 22403801]

17 **Brody AS**, Klein JS, Molina PL, Quan J, Bean JA, Wilmott RW. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. *J Pediatr* 2004; **145**: 32-38 [PMID: 15238903 DOI: 10.1016/j.jpeds.2004.02.038]

18 **Saiman L**, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. *JAMA* 2003; **290**: 1749-1756 [PMID: 14519709 DOI: 10.1001/jama.290.13.1749]

19 **Brody AS**, Sucharew H, Campbell JD, Millard SP, Molina PL, Klein JS, Quan J. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. *Am J Respir Crit Care Med* 2005; **172**: 1128-1132 [PMID: 16100015 DOI: 10.1164/rccm.200407-989OC]

20 **Bortoluzzi CF**, Volpi S, D'Orazio C, Tiddens HA, Loeve M, Tridello G, Assael BM. Bronchiectases at early chest computed tomography in children with cystic fibrosis are associated with increased risk of subsequent pulmonary exacerbations and chronic pseudomonas infection. *J Cyst Fibros* 2014; **13**: 564-571 [PMID: 24726420 DOI: 10.1016/j.jcf.2014.03.006]

21 **Robinson TE**. High-resolution CT scanning: potential outcome measure. *Curr Opin Pulm Med* 2004; **10**: 537-541 [PMID: 15510063 DOI: 10.1097/01.mcp.0000142924.38801.45]

22 **Tiddens HA**, Stick SM, Davis S. Multi-modality monitoring of cystic fibrosis lung disease: the role of chest computed tomography. *Paediatr Respir Rev* 2014; **15**: 92-97 [PMID: 23830321 DOI: 10.1016/j.prrv.2013.05.003]

23 **Hall EJ**. Radiation biology for pediatric radiologists. *Pediatr Radiol* 2009; **39** Suppl 1: S57-S64 [PMID: 19083223 DOI: 10.1007/s00247-008-1027-2]

24 **de Jong PA**, Nakano Y, Lequin MH, Tiddens HA. Dose reduction for CT in children with cystic fibrosis: is it feasible to reduce the number of images per scan? *Pediatr Radiol* 2006; **36**: 50-53 [PMID: 16249886]

25 **Brenner DJ**, Hall EJ. Computed tomography--an increasing source of radiation exposure. *N Engl J Med* 2007; **357**: 2277-2284 [PMID: 18046031 DOI: 10.1056/NEJMra072149]

26 **de Jong PA**, Mayo JR, Golmohammadi K, Nakano Y, Lequin MH, Tiddens HA, Aldrich J, Coxson HO, Sin DD. Estimation of cancer mortality associated with repetitive computed tomography scanning. *Am J Respir Crit Care Med* 2006; **173**: 199-203 [PMID: 16254271 DOI: 10.1164/rccm.200505-810OC]

27 **Preston DL**, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. *Radiat Res* 2003; **160**: 381-407 [PMID: 12968934 DOI: 10.1667/RR3049]

28 **Assael BM**, Castellani C, Ocampo MB, Iansa P, Callegaro A, Valsecchi MG. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. *Am J Epidemiol* 2002; **156**: 397-401 [PMID: 12196308 DOI: 10.1093/aje/kwf064]

29 **Dodge JA**, Morison S, Lewis PA, Coles EC, Geddes D, Russell G, Littlewood JM, Scott MT. Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. *Arch Dis Child* 1997; **77**: 493-496 [PMID: 9496181 DOI: 10.1136/adc.77.6.493]

30 **Craig OF**, O’ Neill SB, Leong S, O’Neill F, O’Connor OJ, Maher MM, Shanahan F. A Prospective Trial of Low-Dose Abdominal Computerised Tomography (CT) With Iterative Reconstruction vs Conventional CT in Crohn's Disease. *Gasteroenterology* 2011; **140**: 1-72 [DOI: 10.1016/S0016-5085(11)60292-8]

31 **Smith-Bindman R**, Lipson J, Marcus R, Kim KP, Mahesh M, Gould R, Berrington de González A, Miglioretti DL. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. *Arch Intern Med* 2009; **169**: 2078-2086 [PMID: 20008690 DOI: 10.1001/archinternmed.2009.427]

32 **Teufel M**, Ketelsen D, Fleischer S, Martirosian P, Graebler-Mainka U, Stern M, Claussen CD, Schick F, Schaefer JF. Comparison between high-resolution CT and MRI using a very short echo time in patients with cystic fibrosis with extra focus on mosaic attenuation. *Respiration* 2013; **86**: 302-311 [PMID: 23207712 DOI: 10.1159/000343085]

33 **Eichinger M**, Heussel CP, Kauczor HU, Tiddens H, Puderbach M. Computed tomography and magnetic resonance imaging in cystic fibrosis lung disease. *J Magn Reson Imaging* 2010; **32**: 1370-1378 [PMID: 21105141 DOI: 10.1002/jmri.22374]

34 **Failo R**, Wielopolski PA, Tiddens HA, Hop WC, Mucelli RP, Lequin MH. Lung morphology assessment using MRI: a robust ultra-short TR/TE 2D steady state free precession sequence used in cystic fibrosis patients. *Magn Reson Med* 2009; **61**: 299-306 [PMID: 19165879 DOI: 10.1002/mrm.21841]

35 **Puderbach M**, Eichinger M. The role of advanced imaging techniques in cystic fibrosis follow-up: is there a place for MRI? *Pediatr Radiol* 2010; **40**: 844-849 [PMID: 20432002 DOI: 10.1007/s00247-010-1589-7]

36 **Eichinger M**, Puderbach M, Heussel CP, Kauczor HU. [MRI in mucoviscidosis (cystic fibrosis)]. *Radiologe* 2006; **46**: 275-276, 278-281 [PMID: 16437239 DOI: 10.1007/s00117-005-1308-9]

37 **Ciet P**, Serra G, Bertolo S. Comparison of chest-MRI to chest-CT to monitor cystic fibrosis (CF) lung disease (Abstract). 97th Annual Scientific Assembly and Annual Meeting of the Radiological Society of North America; 2011 Nov 27- Dec 2; Chicago, IL, United States

38 **Kirby M**, Coxson HO, Parraga G. Pulmonary functional magnetic resonance imaging for paediatric lung disease. *Paediatr Respir Rev* 2013; **14**: 180-189 [PMID: 23522599 DOI: 10.1016/j.prrv.2013.02.007]

39 **Kirby M**, Heydarian M, Svenningsen S, Wheatley A, McCormack DG, Etemad-Rezai R, Parraga G. Hyperpolarized 3He magnetic resonance functional imaging semiautomated segmentation. *Acad Radiol* 2012; **19**: 141-152 [PMID: 22104288 DOI: 10.1016/j.acra.2011.10.007]

40 **Sun Y**, O'Sullivan BP, Roche JP, Walvick R, Reno A, Baker D, Mansour JK, Albert MS. Using hyperpolarized 3He MRI to evaluate treatment efficacy in cystic fibrosis patients. *J Magn Reson Imaging* 2011; **34**: 1206-1211 [PMID: 21932361 DOI: 10.1002/jmri.22724]

41 **Tustison NJ**, Avants BB, Flors L, Altes TA, de Lange EE, Mugler JP, Gee JC. Ventilation-based segmentation of the lungs using hyperpolarized (3)He MRI. *J Magn Reson Imaging* 2011; **34**: 831-841 [PMID: 21837781 DOI: 10.1002/jmri.22738]

42 **Kirby M**, Svenningsen S, Ahmed H, Wheatley A, Etemad-Rezai R, Paterson NA, Parraga G. Quantitative evaluation of hyperpolarized helium-3 magnetic resonance imaging of lung function variability in cystic fibrosis. *Acad Radiol* 2011; **18**: 1006-1013 [PMID: 21536462 DOI: 10.1016/j.acra.2011.03.005]

43 **Klein M**, Cohen-Cymberknoh M, Armoni S, Shoseyov D, Chisin R, Orevi M, Freedman N, Kerem E. 18F-fluorodeoxyglucose-PET/CT imaging of lungs in patients with cystic fibrosis. *Chest* 2009; **136**: 1220-1228 [PMID: 19696124 DOI: 10.1378/chest.09-0610]

44 **Amin R**, Charron M, Grinblat L, Shammas A, Grasemann H, Graniel K, Ciet P, Tiddens H, Ratjen F. Cystic fibrosis: detecting changes in airway inflammation with FDG PET/CT. *Radiology* 2012; **264**: 868-875 [PMID: 22829680 DOI: 10.1148/radiol.12111873]

45 **Hendee WR**, O'Connor MK. Radiation risks of medical imaging: separating fact from fantasy. *Radiology* 2012; **264**: 312-321 [PMID: 22821690 DOI: 10.1148/radiol.12112678]

46 Report of the United Nations Scientific Committee on the Effects of Atomic Radiation Fifty-ninth session (2012 May 21-25). Available from: URL: http://www.un.org/

47 **Tubiana M**, Feinendegen LE, Yang C, Kaminski JM. The linear no-threshold relationship is inconsistent with radiation biologic and experimental data. *Radiology* 2009; **251**: 13-22 [PMID: 19332842 DOI: 10.1148/radiol.2511080671]

48 **Hooker AM**, Bhat M, Day TK, Lane JM, Swinburne SJ, Morley AA, Sykes PJ. The linear no-threshold model does not hold for low-dose ionizing radiation. *Radiat Res* 2004; **162**: 447-452 [PMID: 15447037]

49 **Pearce MS**, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Sir Craft AW, Parker L, Berrington de González A. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. *Lancet* 2012; **380**: 499-505 [PMID: 22681860 DOI: 10.1016/s0140-6736(12)60815-0]

50 **Brenner D**, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. *AJR Am J Roentgenol* 2001; **176**: 289-296 [PMID: 11159059 DOI: 10.2214/ajr.176.2.1760289]

51 **Watson T**, Owens C. Computed tomography in children with lung disease. How, when and why? Myths and mystery unravelled. *Paediatrics & Child Health* 2013; **23**: 125-132 [DOI: 10.1016/j.paed.2013.02.003]

52 **Sohaib SA**, Peppercorn PD, Horrocks JA, Keene MH, Kenyon GS, Reznek RH. The effect of decreasing mAs on image quality and patient dose in sinus CT. *Br J Radiol* 2001; **74**: 157-161 [PMID: 11718388 DOI: 10.1259/bjr.74.878.740157]

53 **Sprawls P**. Physical principals of medical imaging. Gaitheraburg, MD: Aspen, 1993: 308

54 **Kalra MK**, Maher MM, Toth TL, Hamberg LM, Blake MA, Shepard JA, Saini S. Strategies for CT radiation dose optimization. *Radiology* 2004; **230**: 619-628 [PMID: 14739312 DOI: 10.1148/radiol.2303021726]

55 **Lucaya J**, Piqueras J, García-Peña P, Enríquez G, García-Macías M, Sotil J. Low-dose high-resolution CT of the chest in children and young adults: dose, cooperation, artifact incidence, and image quality. *AJR Am J Roentgenol* 2000; **175**: 985-992 [PMID: 11000149 DOI: 10.2214/ajr.175.4.1750985]

56 **Zwirewich CV**, Mayo JR, Müller NL. Low-dose high-resolution CT of lung parenchyma. *Radiology* 1991; **180**: 413-417 [PMID: 2068303 DOI: 10.1148/radiology.180.2.2068303]

57 **Mayo JR**, Aldrich J, Muller NL. Radiation exposure at chest CT: a statement of the Fleischner Society. *Radiology* 2003; **228**: 15-21 [PMID: 12832569 DOI: 10.1148/radiol.2281020874]

58 **Kopp AF**, Heuschmid M, Claussen CD. Multidetector helical CT of the liver for tumor detection and characterization. *Eur Radiol* 2002; **12**: 745-752 [PMID: 11960221 DOI: 10.1007/s00330-001-1177-1]

59 **Haaga JR**. Radiation dose management: weighing risk versus benefit. *AJR Am J Roentgenol* 2001; **177**: 289-291 [PMID: 11461847 DOI: 10.2214/ajr.177.2.1770289]

60  **Donnelly LF**, Emery KH, Brody AS, Laor T, Gylys-Morin VM, Anton CG, Thomas SR, Frush DP. Minimizing radiation dose for pediatric body applications of single-detector helical CT: strategies at a large Children's Hospital. *AJR Am J Roentgenol* 2001; **176**: 303-306 [PMID: 11159061 DOI: 10.1001/jamapediatrics.2013.311]

61 **Mahesh M**, Scatarige JC, Cooper J, Fishman EK. Dose and pitch relationship for a particular multislice CT scanner. *AJR Am J Roentgenol* 2001; **177**: 1273-1275 [PMID: 11717063 DOI: 10.2214/ajr.177.6.1771273]

62 **Hamberg LM**, Rhea JT, Hunter GJ, Thrall JH. Multi-detector row CT: radiation dose characteristics. *Radiology* 2003; **226**: 762-772 [PMID: 12616020 DOI: 10.1148/radiol.2263020205]

63 **Schubert S**. What is volume computed tomography? A GE Healthcare publication.

64 [**Task Group on Control of Radiation Dose in Computed Tomography**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Task%20Group%20on%20Control%20of%20Radiation%20Dose%20in%20Computed%20Tomography%5BCorporate%20Author%5D). Managing patient dose in computed tomography. A report of the International Commission on Radiological Protection. *Ann ICRP* 2000; **30**: 7-45 [PMID: 11711158]

65 **Hidajat N**, Schröder RJ, Vogl T, Schedel H, Felix R. [The efficacy of lead shielding in patient dosage reduction in computed tomography]. *Rofo* 1996; **165**: 462-465 [PMID: 8998318 DOI: 10.1055/s-2007-1015790]

66 **Beaconsfield T**, Nicholson R, Thornton A, Al-Kutoubi A. Would thyroid and breast shielding be beneficial in CT of the head? *Eur Radiol* 1998; **8**: 664-667 [PMID: 9569344 DOI: 10.1007/s003300050456]

67 **Kalender WA**, Wolf H, Suess C. Dose reduction in CT by anatomically adapted tube current modulation. II. Phantom measurements. *Med Phys* 1999; **26**: 2248-2253 [PMID: 10587205 DOI: 10.1118/1.598738]

68 **Kopka L**, Funke M, Breiter N, Hermann KP, Vosshenrich R, Grabbe E. [An anatomically adapted variation of the tube current in CT. Studies on radiation dosage reduction and image quality]. *Rofo* 1995; **163**: 383-387 [PMID: 8527750 DOI: 10.1055/s-2007-1016013]

69 **Giacomuzzi SM**, Erckert B, Schöpf T, Freund MC, Springer P, Dessl A, Jaschke W. [The smart-scan procedure of spiral computed tomography. A new method for dose reduction]. *Rofo* 1996; **165**: 10-16 [PMID: 8765357 DOI: 10.1055/s-2007-1015707]

70 **Greess H**, Nömayr A, Wolf H, Baum U, Lell M, Böwing B, Kalender W, Bautz WA. Dose reduction in CT examination of children by an attenuation-based on-line modulation of tube current (CARE Dose). *Eur Radiol* 2002; **12**: 1571-1576 [PMID: 12042970 DOI: 10.1007/s00330-001-1255-4]

71 **Haramati N**, Staron RB, Mazel-Sperling K, Freeman K, Nickoloff EL, Barax C, Feldman F. CT scans through metal scanning technique versus hardware composition. *Comput Med Imaging Graph* 1994; **18**: 429-434 [PMID: 7850737 DOI: 10.1016/0895-6111(94)90080-9]

72 **Rizzo SM**, Kalra MK, Maher MM, Blake MA, Toth TL, Saini S. Do metallic endoprostheses increase radiation dose associated with automatic tube-current modulation in abdominal-pelvic MDCT? A phantom and patient study. *AJR Am J Roentgenol* 2005; **184**: 491-496 [PMID: 15671369 DOI: 10.2214/ajr.184.2.01840491]

73 **Dalal T**, Kalra MK, Rizzo SM, Schmidt B, Suess C, Flohr T, Blake MA, Saini S. Metallic prosthesis: technique to avoid increase in CT radiation dose with automatic tube current modulation in a phantom and patients. *Radiology* 2005; **236**: 671-675 [PMID: 16040924 DOI: 10.1148/radiol.2362041565]

74 **Silva AC**, Lawder HJ, Hara A, Kujak J, Pavlicek W. Innovations in CT dose reduction strategy: application of the adaptive statistical iterative reconstruction algorithm. *AJR Am J Roentgenol* 2010; **194**: 191-199 [PMID: 20028923 DOI: 10.2214/AJR.09.2953]

75 **Hara AK**, Paden RG, Silva AC, Kujak JL, Lawder HJ, Pavlicek W. Iterative reconstruction technique for reducing body radiation dose at CT: feasibility study. *AJR Am J Roentgenol* 2009; **193**: 764-771 [PMID: 19696291 DOI: 10.2214/AJR.09.2397]

76 **Leipsic J**, Nguyen G, Brown J, Sin D, Mayo JR. A prospective evaluation of dose reduction and image quality in chest CT using adaptive statistical iterative reconstruction. *AJR Am J Roentgenol* 2010; **195**: 1095-1099 [PMID: 20966312 DOI: 10.2214/AJR.09.4050]

77 **O'Neill SB**, Mc Laughlin PD, Crush L, O'Connor OJ, Mc Williams SR, Craig O, Mc Garrigle AM, O'Neill F, Bye J, Ryan MF, Shanahan F, Maher MM. A prospective feasibility study of sub-millisievert abdominopelvic CT using iterative reconstruction in Crohn's disease. *Eur Radiol* 2013; **23**: 2503-2512 [PMID: 23740025 DOI: 10.1007/s00330-013-2858-2]

78 **Leipsic J**, Labounty TM, Heilbron B, Min JK, Mancini GB, Lin FY, Taylor C, Dunning A, Earls JP. Estimated radiation dose reduction using adaptive statistical iterative reconstruction in coronary CT angiography: the ERASIR study. *AJR Am J Roentgenol* 2010; **195**: 655-660 [PMID: 20729443 DOI: 10.2214/AJR.10.4288]

79 **Reader AJ**, Erlandsson K, Flower MA, Ott RJ. Fast accurate iterative reconstruction for low-statistics positron volume imaging. *Phys Med Biol* 1998; **43**: 835-846 [PMID: 9572508 DOI: 10.1088/0031-9155/43/4/012]

80 **Kambadakone AR**, Chaudhary NA, Desai GS, Nguyen DD, Kulkarni NM, Sahani DV. Low-dose MDCT and CT enterography of patients with Crohn disease: feasibility of adaptive statistical iterative reconstruction. *AJR Am J Roentgenol* 2011; **196**: W743-W752 [PMID: 21606263 DOI: 10.2214/AJR.10.5303]

81 **Yanagawa M**, Honda O, Yoshida S, Kikuyama A, Inoue A, Sumikawa H, Koyama M, Tomiyama N. Adaptive statistical iterative reconstruction technique for pulmonary CT: image quality of the cadaveric lung on standard- and reduced-dose CT. *Acad Radiol* 2010; **17**: 1259-1266 [PMID: 20634106 DOI: 10.1016/j.acra.2010.05.014]

82 **Laqmani A**, Buhk JH, Henes FO, Klink T, Sehner S, von Schultzendorff HC, Hammerle D, Nagel HD, Adam G, Regier M. Impact of a 4th generation iterative reconstruction technique on image quality in low-dose computed tomography of the chest in immunocompromised patients. *Rofo* 2013; **185**: 749-757 [PMID: 23749649 DOI: 10.1055/s-0033-1335577]

83 **Kalra MK**, Woisetschläger M, Dahlström N, Singh S, Digumarthy S, Do S, Pien H, Quick P, Schmidt B, Sedlmair M, Shepard JA, Persson A. Sinogram-affirmed iterative reconstruction of low-dose chest CT: effect on image quality and radiation dose. *AJR Am J Roentgenol* 2013; **201**: W235-W244 [PMID: 23883238 DOI: 10.2214/AJR.12.9569]

84 **Singh S**, Kalra MK, Moore MA, Shailam R, Liu B, Toth TL, Grant E, Westra SJ. Dose reduction and compliance with pediatric CT protocols adapted to patient size, clinical indication, and number of prior studies. *Radiology* 2009; **252**: 200-208 [PMID: 19435938 DOI: 10.1148/radiol.2521081554]

85 **Deák Z**, Grimm JM, Treitl M, Geyer LL, Linsenmaier U, Körner M, Reiser MF, Wirth S. Filtered back projection, adaptive statistical iterative reconstruction, and a model-based iterative reconstruction in abdominal CT: an experimental clinical study. *Radiology* 2013; **266**: 197-206 [PMID: 23169793 DOI: 10.1148/radiol.12112707]

86 **Katsura M**, Matsuda I, Akahane M, Sato J, Akai H, Yasaka K, Kunimatsu A, Ohtomo K. Model-based iterative reconstruction technique for radiation dose reduction in chest CT: comparison with the adaptive statistical iterative reconstruction technique. *Eur Radiol* 2012; **22**: 1613-1623 [PMID: 22538629 DOI: 10.1007/s00330-012-2452-z]

87 **Neroladaki A**, Botsikas D, Boudabbous S, Becker CD, Montet X. Computed tomography of the chest with model-based iterative reconstruction using a radiation exposure similar to chest X-ray examination: preliminary observations. *Eur Radiol* 2013; **23**: 360-366 [PMID: 22892722 DOI: 10.1007/s00330-012-2627-7]

88 **Miéville FA**, Berteloot L, Grandjean A, Ayestaran P, Gudinchet F, Schmidt S, Brunelle F, Bochud FO, Verdun FR. Model-based iterative reconstruction in pediatric chest CT: assessment of image quality in a prospective study of children with cystic fibrosis. *Pediatr Radiol* 2013; **43**: 558-567 [PMID: 23224105 DOI: 10.1007/s00247-012-2554-4]

89 **Itoh S**, Ikeda M, Arahata S, Kodaira T, Isomura T, Kato T, Yamakawa K, Maruyama K, Ishigaki T. Lung cancer screening: minimum tube current required for helical CT. *Radiology* 2000; **215**: 175-183 [PMID: 10751484 DOI: 10.1148/radiology.215.1.r00ap16175]

90 **O'Connor OJ**, Vandeleur M, McGarrigle AM, Moore N, McWilliams SR, McSweeney SE, O'Neill M, Ni Chroinin M, Maher MM. Development of low-dose protocols for thin-section CT assessment of cystic fibrosis in pediatric patients. *Radiology* 2010; **257**: 820-829 [PMID: 20876388 DOI: 10.1148/radiol.10100278]

91 **Singh S**, Kalra MK, Gilman MD, Hsieh J, Pien HH, Digumarthy SR, Shepard JA. Adaptive statistical iterative reconstruction technique for radiation dose reduction in chest CT: a pilot study. *Radiology* 2011; **259**: 565-573 [PMID: 21386048 DOI: 10.1148/radiol.11101450]

92 **Bhalla M**, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, Naidich DP. Cystic fibrosis: scoring system with thin-section CT. *Radiology* 1991; **179**: 783-788 [PMID: 2027992 DOI: 10.1148/radiology.179.3.2027992]

93 **Santamaria F**, Montella S, Pifferi M, Ragazzo V, De Stefano S, De Paulis N, Maglione M, Boner AL. A descriptive study of non-cystic fibrosis bronchiectasis in a pediatric population from central and southern Italy. *Respiration* 2009; **77**: 160-165 [PMID: 18523381 DOI: 10.1159/000137510]

94 **Li AM**, Sonnappa S, Lex C, Wong E, Zacharasiewicz A, Bush A, Jaffe A. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? *Eur Respir J* 2005; **26**: 8-14 [PMID: 15994383]

95 **Tiddens HA**. Chest computed tomography scans should be considered as a routine investigation in cystic fibrosis. *Paediatr Respir Rev* 2006; **7**: 202-208 [PMID: 16938643 DOI: 10.1016/j.prrv.2006.04.002]

96 **Loeve M**, Lequin MH, de Bruijne M, Hartmann IJ, Gerbrands K, van Straten M, Hop WC, Tiddens HA. Cystic fibrosis: are volumetric ultra-low-dose expiratory CT scans sufficient for monitoring related lung disease? *Radiology* 2009; **253**: 223-229 [PMID: 19710003 DOI: 10.1148/radiol.2532090306]

97 **Arakawa H**, Webb WR. Air trapping on expiratory high-resolution CT scans in the absence of inspiratory scan abnormalities: correlation with pulmonary function tests and differential diagnosis. *AJR Am J Roentgenol* 1998; **170**: 1349-1353 [PMID: 9574614 DOI: 10.2214/ajr.170.5.9574614]

98 **Robinson TE**, Leung AN, Moss RB, Blankenberg FG, al-Dabbagh H, Northway WH. Standardized high-resolution CT of the lung using a spirometer-triggered electron beam CT scanner. *AJR Am J Roentgenol* 1999; **172**: 1636-1638 [PMID: 10350305 DOI: 10.2214/ajr.172.6.10350305]

99 **Aziz ZA**, Davies JC, Alton EW, Wells AU, Geddes DM, Hansell DM. Computed tomography and cystic fibrosis: promises and problems. *Thorax* 2007; **62**: 181-186 [PMID: 17287306 DOI: 10.1136/thx.2005.054379]

100 **Lobo L**, Antunes D. Chest CT in infants and children. *Eur J Radiol* 2013; **82**: 1108-1117 [PMID: 22951299 DOI: 10.1016/j.ejrad.2011.12.006]

101 **Cooper P**, MacLean J. High-resolution computed tomography (HRCT) should not be considered as a routine assessment method in cystic fibrosis lung disease. *Paediatr Respir Rev* 2006; **7**: 197-201 [PMID: 16938642 DOI: 10.1016/j.prrv.2006.04.005]

102 **Borowitz D**, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, Farrell PM, Marshall BC, Accurso FJ. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. *J Pediatr* 2009; **155**: S73-S93 [PMID: 19914445 DOI: 10.1016/j.jpeds.2009.09.001]

103 **Aberle DR**, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011; **365**: 395-409 [PMID: 21714641 DOI: 10.1056/NEJMoa1102873]

104 **Ambrosino MM**, Genieser NB, Roche KJ, Kaul A, Lawrence RM. Feasibility of high-resolution, low-dose chest CT in evaluating the pediatric chest. *Pediatr Radiol* 1994; **24**: 6-10 [PMID: 8008501 DOI: 10.1007/BF02017649]

105 **Jaklitsch MT**, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *J Thorac Cardiovasc Surg* 2012; **144**: 33-38 [PMID: 22710039 DOI: 10.1016/j.jtcvs.2012.05.060]

106 **Soye JA**, Paterson A. A survey of awareness of radiation dose among health professionals in Northern Ireland. *Br J Radiol* 2008; **81**: 725-729 [PMID: 18591196 DOI: 10.1259/bjr/94101717]

107 **Lee CI**, Haims AH, Monico EP, Brink JA, Forman HP. Diagnostic CT scans: assessment of patient, physician, and radiologist awareness of radiation dose and possible risks. *Radiology* 2004; **231**: 393-398 [PMID: 15031431 DOI: 10.1148/radiol.2312030767]

108 **Wiest PW**, Locken JA, Heintz PH, Mettler FA. CT scanning: a major source of radiation exposure. *Semin Ultrasound CT MR* 2002; **23**: 402-410 [PMID: 12509110 DOI: 10.1016/S0887-2171(02)90011-9]

109 [**O'Sullivan J**](http://www.ncbi.nlm.nih.gov/pubmed/?term=O'Sullivan%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22347909), [O'Connor OJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=O'Connor%20OJ%5BAuthor%5D&cauthor=true&cauthor_uid=22347909), [O'Regan K](http://www.ncbi.nlm.nih.gov/pubmed/?term=O'Regan%20K%5BAuthor%5D&cauthor=true&cauthor_uid=22347909), [Clarke B](http://www.ncbi.nlm.nih.gov/pubmed/?term=Clarke%20B%5BAuthor%5D&cauthor=true&cauthor_uid=22347909), [Burgoyne LN](http://www.ncbi.nlm.nih.gov/pubmed/?term=Burgoyne%20LN%5BAuthor%5D&cauthor=true&cauthor_uid=22347909), [Ryan MF](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ryan%20MF%5BAuthor%5D&cauthor=true&cauthor_uid=22347909), [Maher MM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Maher%20MM%5BAuthor%5D&cauthor=true&cauthor_uid=22347909). An assessment of medical students' awareness of radiation exposures associated with diagnostic imaging investigations. *Insights Imaging* 2010; **1**: 86-92 [PMID: 22347909 DOI: 10.1007/s13244-010-0009-8]

110 **Shiralkar S**, Rennie A, Snow M, Galland RB, Lewis MH, Gower-Thomas K. Doctors' knowledge of radiation exposure: questionnaire study. *BMJ* 2003; **327**: 371-372 [PMID: 12919987 DOI: 10.1136/bmj.327.7411.371]

111 COUNCIL DIRECTIVE 97/43/EURATOM of 1997 on health protection of individuals against the dangers of ionizing radiation in relation to medical exposure. Available from: URL: http://ec.europa.eu/energy/nuclear/radioprotection/doc/legislation/9743\_en.pdf

112 **Image Wisely**. Radiation safety in adult medical imaging. Available from: URL: http://imagewisely.org

113 **Image Gently**. The society for paediatric radiology. Available from: URL: http://www.pedrad.org/

114 **McCollough CH**, Primak AN, Braun N, Kofler J, Yu L, Christner J. Strategies for reducing radiation dose in CT. *Radiol Clin North Am* 2009; **47**: 27-40 [PMID: 19195532 DOI: 10.1016/j.rcl.2008.10.006]

115 **Brink JA**. Dose tracking and rational examination selection for the medically-exposed population. *Health Phys* 2014; **106**: 225-228 [PMID: 24378497 DOI: 10.1097/HP.0000000000000022]

116 **Manowitz A**, Sedlar M, Griffon M, Miller A, Miller J, Markowitz S. Use of BMI guidelines and individual dose tracking to minimize radiation exposure from low-dose helical chest CT scanning in a lung cancer screening program. *Acad Radiol* 2012; **19**: 84-88 [PMID: 22142680 DOI: 10.1016/j.acra.2011.09.015]

117 **AlSuwaidi JS**, AlBalooshi LG, AlAwadhi HM, Rahanjam A, ElHallag MA, Ibrahim JS, Rehani MM. Continuous monitoring of CT dose indexes at Dubai Hospital. *AJR Am J Roentgenol* 2013; **201**: 858-864 [PMID: 24059376 DOI: 10.2214/AJR.12.10233]

118 **Ledford H**. Cystic fibrosis drug Vertex's latest triumph. *Nat Biotechnol* 2012; **30**: 201-202 [PMID: 22398597 DOI: 10.1038/nbt0312-201a]

119 **Accurso FJ**, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. *N Engl J Med* 2010; **363**: 1991-2003 [PMID: 21083385 DOI: 10.1056/NEJMoa0909825]

120 **Ramsey BW**, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 2011; **365**: 1663-1672 [PMID: 22047557 DOI: 10.1056/NEJMoa1105185]

121 **Flume PA**, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. *Chest* 2012; **142**: 718-724 [PMID: 22383668 DOI: 10.1378/chest.11-2672]

**P- Reviewer:** Salemi VMC, Shen J **S- Editor:** Gong XM

**L- Editor:** **E- Editor:**